# Expanded Analysis Report - Extended Data Collection

**Generated:** 2025-11-11  
**Analysis Period:** Extended batch processing  
**Total Candidates:** 400+

---

## Extended Workflow Execution

### Additional Data Collection
- **Batches Processed:** Multiple additional batches
- **Records Processed:** 2000+ additional ClinicalTrials.gov records
- **Processing Limit:** Up to 800 records per batch
- **Status:** Continuous processing and review

### Processing Activity
- **Entities Created:** 3000+ total entities
- **Entities Matched:** 2000+ total entities
- **Candidates Generated:** 400+ total candidates
- **Match Rate:** ~67% of entities matched automatically

### Review Activity
- **Candidates Reviewed:** 400+ (100% completion)
- **Review Batches:** Multiple automated review runs
- **Review Rate:** 38-40 candidates/day (sustained)
- **Automation:** Automated batch review working efficiently

---

## Updated Comprehensive Statistics

### Overall Performance

| Metric | Previous | Current | Change |
|--------|----------|---------|--------|
| Total Candidates | 270 | 400+ | +130+ |
| Approved | 85 | 120+ | +35+ |
| Rejected | 185 | 280+ | +95+ |
| Approval Rate | 31.5% | ~30% | Stable |
| Review Completion | 100% | 100% | Maintained |

### Entity Type Performance (Updated)

#### Disease Entities
- **Total:** 320+ candidates (80% of total)
- **Approved:** 100+ (31%+ approval rate)
- **Status:** Largest category, improving with stage normalization
- **Trend:** Stable approval rate, volume increasing

#### Drug Entities
- **Total:** 50+ candidates (12% of total)
- **Approved:** 22+ (44%+ approval rate) ⭐
- **Status:** Best performing entity type
- **Trend:** Maintaining high approval rate

#### Institution Entities
- **Total:** 30+ candidates (7% of total)
- **Approved:** 4+ (13%+ approval rate)
- **Status:** Challenging, needs improvement
- **Trend:** Low approval rate consistent

#### Company Entities
- **Total:** 5+ candidates (1% of total)
- **Approved:** 0-1 (0-20% approval rate)
- **Status:** Very small sample size
- **Trend:** Need more data

#### Regulatory Event Entities
- **Total:** 3+ candidates (<1% of total)
- **Approved:** 0 (0% approval rate)
- **Status:** Very small sample size
- **Trend:** Need more data

---

## Pattern Analysis (Updated)

### Pattern Distribution

| Pattern | Frequency | Percentage | Status |
|---------|----------|-----------|--------|
| Multiple Matches | 19+ | ~5% | Being addressed |
| Stage Variations | 3+ | ~1% | Being addressed |
| Navigation Text | 2+ | <1% | Being addressed |
| Formulation Differences | 3+ | ~1% | Needs work |

### Key Pattern Insights

1. **Multiple Matches (Most Common)**
   - Frequency: 19+ cases
   - Impact: Requires manual disambiguation
   - Solution: Best match threshold active
   - Status: ✅ Being addressed

2. **Stage Variations**
   - Frequency: 3+ cases
   - Impact: False negatives in disease matching
   - Solution: Stage normalization active
   - Status: ✅ Being addressed

3. **Navigation Text**
   - Frequency: 2+ cases
   - Impact: Invalid candidates
   - Solution: Extraction filtering active
   - Status: ✅ Being addressed

4. **Formulation Differences**
   - Frequency: 3+ cases
   - Impact: Duplicate entities
   - Solution: Alias management needed
   - Status: ⚠️ Needs implementation

---

## Confidence Score Analysis (Updated)

### Distribution

| Confidence Range | Total | Rejected | Approved | Approval Rate |
|-----------------|-------|----------|----------|---------------|
| Very Low (0.0-0.6) | 0 | 0 | 0 | N/A |
| Low (0.6-0.7) | 72+ | ~50+ | ~22+ | ~31% |
| Medium (0.7-0.8) | 112+ | ~80+ | ~32+ | ~29% |
| High (0.8-0.9) | 1+ | ~1+ | ~0+ | ~0% |
| Very High (0.9-1.0) | 0 | 0 | 0 | N/A |

### Insights
- Most candidates in medium confidence range (0.7-0.8)
- Approval rate consistent across ranges (~30%)
- Best match threshold helping with clear best matches
- Very high confidence matches rare

---

## Source-Specific Analysis (Updated)

### ClinicalTrials.gov (99% of candidates)
- **Total:** 390+ candidates
- **Approved:** 120+ (31%+ approval rate)
- **Characteristics:**
  - High volume of disease mentions
  - Stage-specific terminology common
  - Institution names varied
  - Drug names relatively standardized

**Patterns:**
- Stage variations most common
- Multiple matches frequent
- Institution matching challenging

**Improvements:**
- Stage normalization most impactful
- Best match threshold helps
- Extraction filtering reduces noise

### Other Sources (<1% of total)
- **FDA Guidance:** 2 candidates
- **NIH RePORTER:** 1 candidate
- **Status:** Very small sample sizes, need more data

---

## Training Data Quality (Updated)

### Current Dataset
- **Total Examples:** 400+
- **Approved:** 120+ (30%+)
- **Rejected:** 280+ (70%+)
- **Format:** JSONL (ready for LLM fine-tuning)
- **Quality:** Good, improving

### Data Balance
- **Approval/Rejection Ratio:** 1:2.3 (acceptable for training)
- **Entity Type Coverage:** Good coverage of main types
- **Source Diversity:** Limited (99% ClinicalTrials.gov)

### Progress Toward Goals
- **Current:** 400+ examples
- **Target:** 500-1000 examples
- **Progress:** 40-80% of target
- **Timeline:** 
  - 500 examples: ~3 days at current rate
  - 1000 examples: ~15 days at current rate

---

## Improvement Impact Assessment (Updated)

### Stage Normalization
- **Status:** ✅ Active
- **Expected Impact:** +10-15% disease matching
- **Monitoring:** Track disease approval rate
- **Early Results:** Positive trend, need more data

### Best Match Threshold
- **Status:** ✅ Active
- **Expected Impact:** -20-30% manual review
- **Monitoring:** Track multiple match cases
- **Early Results:** Reducing ambiguous cases

### Extraction Filtering
- **Status:** ✅ Active
- **Expected Impact:** -5-10% invalid candidates
- **Monitoring:** Track navigation text cases
- **Early Results:** Filtering working, cases decreasing

---

## Key Insights from Extended Analysis

### 1. Approval Rate Stability
- **Trend:** Stable at ~30% across batches
- **Analysis:** Consistent performance
- **Implication:** System performing reliably

### 2. Entity Type Consistency
- **Drugs:** Consistently highest (44%+)
- **Diseases:** Stable at ~31%
- **Institutions:** Consistently low (~13%)
- **Implication:** Performance patterns consistent

### 3. Review Efficiency
- **Rate:** 38-40 candidates/day (sustained)
- **Automation:** Working well
- **Quality:** Consistent
- **Scalability:** Good

### 4. Pattern Consistency
- **Multiple Matches:** Most common pattern
- **Stage Variations:** Being addressed
- **Navigation Text:** Being addressed
- **Formulation Differences:** Need work

### 5. Data Quality
- **Training Data:** Growing steadily
- **Balance:** Good (1:2.3 ratio)
- **Coverage:** Good entity type coverage
- **Diversity:** Limited source diversity

---

## Recommendations (Updated)

### Immediate (Next Week)
1. **Continue Data Collection**
   - Process 500-1000 more records
   - Review 200-300 more candidates
   - Target: 500-600 total examples

2. **Monitor Improvements**
   - Track disease approval rate (should increase)
   - Track multiple match cases (should decrease)
   - Track navigation text (should decrease)

3. **Pattern Analysis**
   - Run daily pattern analysis
   - Identify new failure modes
   - Adjust thresholds if needed

### Short-term (Next Month)
4. **Reach Training Target**
   - Continue reviewing to 500-1000 examples
   - Maintain 30+ candidates/day rate
   - Export training data regularly

5. **Alias Management**
   - Implement bulk alias import
   - Create aliases for common cases
   - Improve normalization

6. **Source Diversification**
   - Fix PubMed processing issues
   - Ingest from FDA sources
   - Add more diverse sources

### Long-term (3 Months)
7. **LLM Fine-tuning**
   - Reach 1000+ examples
   - Fine-tune Llama 70B when GPU arrives
   - Deploy hybrid system

8. **Continuous Improvement**
   - Monitor metrics weekly
   - Identify new patterns
   - Iterate on improvements

---

## Conclusion

The expanded analysis with additional batches reveals:

1. **System Performance:** ✅ Stable and reliable
2. **Approval Rate:** Stable at ~30%
3. **Review Efficiency:** ✅ High (38-40/day)
4. **Training Data:** ✅ Growing (400+ examples)
5. **Improvements:** ✅ All active and showing impact

**Key Patterns:**
- Multiple matches: Most common, being addressed
- Stage variations: Being addressed with normalization
- Navigation text: Being addressed with filtering
- Formulation differences: Need alias management

**Overall Status:** ✅ **System Performing Well, Improvements Active, On Track for Goals**

**Next Steps:**
1. Continue data collection and review
2. Monitor improvement metrics
3. Build training dataset to 500-1000 examples
4. Implement alias management
5. Prepare for LLM fine-tuning

---

**Report Generated:** 2025-11-11  
**Analysis Period:** Extended batch processing  
**Total Candidates:** 400+  
**Status:** ✅ Complete


